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A 36-year-old female former smoker presented with aproductive cough. One year after visiting our hospital
in February 2008, chest computed tomography (CT) re-
vealed diffuse bilateral pulmonary nodules combined with
a consolidation shadow (Figure 1A). A definite diagnosis
could not be made by bronchofiberscopic examination;
however, CT-guided needle biopsy specimens revealed
bronchioloalveolar carcinoma (BAC) of mucinous subtype
(Figure 2). Her clinical stage was T4N2M1a according to
the seventh edition of the tumor, node, metastasis classi-
fication. Activating epidermal growth factor receptor
(EGFR) gene mutations were not detected in her biopsy
specimens. She received chemotherapy with gemcitabine
and carboplatin as her first-line chemotherapy; however,
her disease progressed after four cycles of chemotherapy.
She then received further chemotherapy with docetaxel,
erlotinib, paclitaxel, and irinotecan; however, neither reg-
imen was effective, and her symptoms worsened. In May
2009, pemetrexed was approved for non-small cell lung
cancer in Japan and was chosen as her sixth-line regimen
and started in June 2009. The initial dose of pemetrexed
was 500 mg/m2 with vitamin B12 and folic acid supple-
mentation. Chest CT after the two cycles of chemotherapy
showed a radiographic response, and her symptoms also
improved. The dose of pemetrexed was reduced to 400
mg/m2 from the fourth cycle because of grade 3 liver
dysfunction (Common Terminology Criteria for Adverse
Events, version 3). Other adverse events were urticaria,
skin hyperpigmentation, and general fatigue; however,
they were all generally mild. Chest CT showed continuous
improvement (Figure 1B, C), and her liver function has
been stable since the dose reduction. Pemetrexed is cur-
rently being administered for its 20th cycle, and she is
doing very well.
DISCUSSION
BAC is a distinctive form of lung adenocarcinoma
and is further divided into two subtypes: mucinous and
nonmucinous.1 Although approximately 20% of adenocar-
cinomas have BAC features, “pure” BAC represents less
than 5% of adenocarcinomas.2 Historically, BAC was
believed to be rather refractory to cytotoxic chemotherapy,
and it is still debatable whether cytotoxic chemotherapy is
equally effective in BAC and other types of adenocarci-
noma.2 Recently, it became widely known that the fre-
quency of activating mutations of EGFR, the strongest
predictive factor of a response to EGFR tyrosine kinase
inhibitors, such as gefitinib and erlotinib, is significantly
higher in BAC3; however, the frequency of EGFR muta-
tions is significantly lower in the mucinous subtype than in
the nonmucinous subtype.4
Our patient presented with BAC of the mucinous
subtype, and her tumor did not express activating EGFR
mutations. She received multiple lines of chemotherapy,
including platinum based, docetaxel, and erlotinib; how-
ever, only pemetrexed was effective.
Pemetrexed is a multitargeted antifolate agent and
has been approved as standard first-line (combination with
platinum) and second-line chemotherapy for non-small
cell lung cancer, and more recently, maintenance chemo-
therapy with pemetrexed has been under debate. Interest-
ingly, pemetrexed is significantly more effective for
nonsquamous than squamous histology.5 One possible ex-
planation is that the expression of thymidylate synthase,
one of the molecular targets of pemetrexed, is generally
higher in squamous than nonsquamous histology; however,
it needs further confirmation.
We performed immunohistochemical examination to
detect the echinoderm microtubule-associated protein-like
4 gene and the anaplastic lymphoma kinase gene, fusion
gene, using the intercalating antibody-enhanced polymer
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method6; however, her tumor did not harbor the echino-
derm microtubule-associated protein-like 4 gene and the
anaplastic lymphoma kinase gene, fusion gene.
Finally, pemetrexed was safely administered for
more than 1 year to our patient without deterioration of the
performance status. This may also indicate the usefulness
of pemetrexed as maintenance chemotherapy. Further in-
vestigations of pemetrexed are needed in patients with
BAC.
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FIGURE 1. Computed tomogra-
phy (CT) of the chest showed dif-
fuse bilateral pulmonary nodules
combined with consolidation
shadow before pemetrexed treat-
ment (A). CT after 12 cycles (B) and
18 cycles (C) showed continuous
improvement of the shadow.
FIGURE 2. Biopsy specimen. There are a few fragments of
columnar tumor cells containing mucin in the cytoplasm
(hematoxylin and eosin stained).
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